Key result
Intensive glycemic control cuts diabetic retinopathy progression ~33% at 4 years, while BP control fails.
RCT (n=2,856)
Placebo-controlled (dyslipidemia arm)
Randomized
Answers are grounded in this paper and cite their sources.
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
No takes yet. Share an insight, caveat, or question.
A 2010 study conducted an RCT in Type 2 diabetes and diabetic retinopathy (n=2,856). Intensive glycemic control (HbA1c <6.0%), intensive dyslipidemia therapy (fenofibrate plus simvastatin), or intensive blood-pressure control (SBP <120 mm Hg) vs. Standard glycemic control (HbA1c 7.0-7.9%), placebo plus simvastatin, or standard blood-pressure control (SBP <140 mm Hg) was evaluated on Progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale or development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy at 4 years (OR 0.67, 95% CI 0.51-0.87, p=0.003). Intensive glycemic control and fenofibrate plus simvastatin, unlike intensive BP control, reduced diabetic retinopathy progression at 4 years.
Synapse has enriched 10 related papers. Consider them for comparative context: